Prof. Sebahat Ocak discusses the 3-year overall survival data of the phase III, randomized controlled CASPIAN trial (French)
In this episode, Prof. Dr. Sebahat Ocak (CHU UCL Namur Site Godinne) discusses the most recent results of the phase III CASPIAN trial, evaluating the combination of platinum-etoposide and the immune checkpoint inhibitor durvalumab as first-line treatment for patients with extensive-stage small cell lung cancer.
This podcast episode was sponsored by AstraZeneca. Imfinzi® (durvalumab) is indicated as first-line treatment of ES-SCLC, in combination with etoposide and carboplatin or cisplatin.
(NS ID XL-2634-Revision date 04/2022-WEB Local code 430). Click here for the SmPC